tradingkey.logo

CVRx Inc

CVRX
9.710USD
-0.340-3.38%
Cierre 11/07, 16:00ETCotizaciones retrasadas 15 min
254.34MCap. mercado
PérdidaP/E TTM

Más Datos de CVRx Inc Compañía

CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.

Información de CVRx Inc

Símbolo de cotizaciónCVRX
Nombre de la empresaCVRx Inc
Fecha de salida a bolsaJun 30, 2021
Director ejecutivoMr. Kevin Hykes
Número de empleados206
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 30
Dirección9201 West Broadway Avenue
CiudadMINNEAPOLIS
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal55445
Teléfono17634162850
Sitio Webhttps://www.cvrx.com/
Símbolo de cotizaciónCVRX
Fecha de salida a bolsaJun 30, 2021
Director ejecutivoMr. Kevin Hykes

Ejecutivos de CVRx Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Kevin Hykes
Mr. Kevin Hykes
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
35.00K
+16.67%
Mr. Joseph P. (Joe) Slattery, CPA
Mr. Joseph P. (Joe) Slattery, CPA
Lead Independent Director
Lead Independent Director
30.64K
--
Mr. Paul Verrastro
Mr. Paul Verrastro
Chief Marketing and Strategy Officer
Chief Marketing and Strategy Officer
16.84K
+1916.17%
Mr. Brent Binkowski
Mr. Brent Binkowski
Chief Operating Officer
Chief Operating Officer
16.60K
--
Mr. Jared Oasheim
Mr. Jared Oasheim
Chief Financial Officer
Chief Financial Officer
15.45K
-58.75%
Ms. Martha Shadan
Ms. Martha Shadan
Independent Director
Independent Director
--
--
Dr. Mudit K. Jain, Ph.D.
Dr. Mudit K. Jain, Ph.D.
Independent Director
Independent Director
--
--
Dr. Philip B. Adamson
Dr. Philip B. Adamson
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Kevin Ballinger
Mr. Kevin Ballinger
Independent Director
Independent Director
--
--
Mr. Kirk Nielsen
Mr. Kirk Nielsen
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Kevin Hykes
Mr. Kevin Hykes
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
35.00K
+16.67%
Mr. Joseph P. (Joe) Slattery, CPA
Mr. Joseph P. (Joe) Slattery, CPA
Lead Independent Director
Lead Independent Director
30.64K
--
Mr. Paul Verrastro
Mr. Paul Verrastro
Chief Marketing and Strategy Officer
Chief Marketing and Strategy Officer
16.84K
+1916.17%
Mr. Brent Binkowski
Mr. Brent Binkowski
Chief Operating Officer
Chief Operating Officer
16.60K
--
Mr. Jared Oasheim
Mr. Jared Oasheim
Chief Financial Officer
Chief Financial Officer
15.45K
-58.75%
Ms. Martha Shadan
Ms. Martha Shadan
Independent Director
Independent Director
--
--

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
US
12.24M
90.09%
Others
1.35M
9.91%
Por negocio
Por región
Sin datos

Estadísticas de accionistas

Actualizado: vie., 15 de ago
Actualizado: vie., 15 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Johnson & Johnson Innovation-JJDC, Inc.
15.69%
New Enterprise Associates (NEA)
7.75%
Vensana Capital Management LLC
6.54%
Gilde Equity Management Benelux B.V.
4.70%
The Vanguard Group, Inc.
4.16%
Otro
61.16%
Accionistas
Accionistas
Proporción
Johnson & Johnson Innovation-JJDC, Inc.
15.69%
New Enterprise Associates (NEA)
7.75%
Vensana Capital Management LLC
6.54%
Gilde Equity Management Benelux B.V.
4.70%
The Vanguard Group, Inc.
4.16%
Otro
61.16%
Tipos de accionistas
Accionistas
Proporción
Venture Capital
30.08%
Hedge Fund
11.81%
Investment Advisor
10.75%
Investment Advisor/Hedge Fund
7.10%
Private Equity
4.70%
Individual Investor
4.33%
Research Firm
2.49%
Pension Fund
0.48%
Bank and Trust
0.14%
Otro
28.11%

Participación institucional

Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
222
17.67M
67.56%
-3.51M
2025Q2
224
19.50M
74.57%
-2.62M
2025Q1
230
20.50M
79.42%
-1.80M
2024Q4
227
19.61M
76.88%
-3.77M
2024Q3
217
19.64M
83.65%
-2.97M
2024Q2
213
19.05M
87.80%
-3.48M
2024Q1
210
19.25M
90.15%
-2.13M
2023Q4
205
18.10M
86.79%
-3.35M
2023Q3
199
16.55M
79.64%
-6.10M
2023Q2
210
16.13M
77.85%
-6.03M
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Johnson & Johnson Innovation-JJDC, Inc.
4.10M
15.69%
--
--
Jun 30, 2025
New Enterprise Associates (NEA)
2.03M
7.75%
--
--
Jun 30, 2025
Vensana Capital Management LLC
1.71M
6.54%
--
--
Dec 31, 2024
Gilde Equity Management Benelux B.V.
1.23M
4.7%
-136.72K
-10.01%
Feb 04, 2025
The Vanguard Group, Inc.
1.08M
4.12%
+70.56K
+7.01%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
949.05K
3.63%
+27.13K
+2.94%
Jun 30, 2025
Jain (Mudit Kumar)
938.43K
3.59%
+1.65K
+0.18%
May 13, 2025
Parkman Healthcare Partners LLC
789.10K
3.02%
-440.42K
-35.82%
Jun 30, 2025
Balyasny Asset Management LP
674.68K
2.58%
+267.06K
+65.52%
Jun 30, 2025
Geode Capital Management, L.L.C.
382.44K
1.46%
+23.08K
+6.42%
Jun 30, 2025
Ver más

ETFs relacionados

Actualizado: jue., 6 de nov
Actualizado: jue., 6 de nov
Nombre
Proporción
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
JPMorgan Fundamental Data Science Small Core ETF
0%
iShares Russell 2000 Value ETF
0%
Avantis US Small Cap Equity ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Vanguard US Momentum Factor ETF
0%
Avantis US Equity ETF
0%
Ver más
iShares Micro-Cap ETF
Proporción0.02%
iShares Russell 2000 Growth ETF
Proporción0.01%
JPMorgan Fundamental Data Science Small Core ETF
Proporción0%
iShares Russell 2000 Value ETF
Proporción0%
Avantis US Small Cap Equity ETF
Proporción0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporción0%
DFA Dimensional US Sustainability Core 1 ETF
Proporción0%
Vanguard US Momentum Factor ETF
Proporción0%
Avantis US Equity ETF
Proporción0%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
KeyAI